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Abstract
Background: Classical Galactosemia (CG) is an inborn error of galactose metabolism caused by the deficiency of
the galactose-1-phosphate uridyltransferase enzyme. It is transmitted as an autosomal recessive disease and is
typically characterized by neonatal galactose intolerance, with complications ranging from neonatal jaundice and
liver failure to late complications, such as motor and reproductive dysfunctions. Galactosemia is also heterogeneous
from a molecular standpoint, with hundreds of different mutations described in the GALT gene, some of them
specific to certain populations, reflecting consequence of founder effect.
Methods: This study reviews the main clinical findings and depicts the spectrum of mutations identified in 19
patients with CG, six with Duarte Galactosemia and one with type 2 Galactosemia in Brazil. Some individuals were
diagnosed through expanded newborn screening test, which is not available routinely to all newborns.
Results: The main classical Galactosemia mutations reported to date were identified in this study, as well as the Duarte
variant and seven novel mutations - c.2 T > C (p.M1T), c.97C > A (p.R33S), c.217C > T (p.P73S), c.328 + 1G > A (IVS3 +
1G > A), c.377 + 4A > C (IVS4 + 4A > C), c.287_289delACA (p.N97del) and c.506A > C (p.Q169P). This was expected, given
the high miscegenation of the Brazilian population.
Conclusions: This study expands the mutation spectrum in GALT gene and reinforces the importance of early
diagnosis and introduction of dietary treatment, what is possible with the introduction of Galactosemia in
neonatal screening programs.
Keywords: GALT, Inborn error of galactose metabolism, Mutation screening
Background
The ubiquitously expressed enzyme galactose-1-phosphate
uridyltransferase (GALT; EC 2.7.7.12) is a component of
the galactose metabolism pathway that catalyzes the con-
version of galactose-1-phosphate with UDP glucose to
glucose- 1-phosphate and UDP galactose [1, 2]. Its defi-
ciency causes classical galactosemia [CG; MIM#230400]
[3], which is presented in the neonatal period as poor
feeding, vomiting, diarrhea, jaundice, liver and renal failure,
hypoglycemia, muscular hypotonia, sepsis and cataract
[4, 5]. The treatment is the diet restriction of lactose-
containing foods, which reverses the majority of neonatal
symptoms, but does not prevent late complications such
as impairment of mental development, disorders of speech
and motor function, and reproductive system abnor-
malities in some cases [6–14]. The cDNA of the gene
that encodes GALT (NG_009029.1) was cloned and
characterized by Reichardt and Berg (1988) [15], it is
located on chromosome 9p13 [16] with approximately
4 kb of DNA sequence arranged into 11 exons. The CG
is inherited as an autosomal recessive disease and 336
different mutations have been identified so far [17].
Classical Galactosemia is heterogeneous at clinical and
molecular level, but there are some common mutations,
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as the c.563A >G (p.Q188R) and the c.855G >T (p.K285N)
[18–20] in Caucasian populations and the c.404C >T
p.S135L [21, 22] in individuals of African origin. Besides
the deleterious mutations, the most common GALTmutant
is Duarte 2 (D2) allele, characterized by some sequence
changes: a c.940A > G (p.N314D) missense substitution,
three intronic base changes and a 4 bp deletion in the
5′ proximal sequence [23–25]. The D2 allele in heterozygous
with one allele of CG causes a mild type of galactosemia,
called Duarte galactosemia. Apart from GALT defi-
ciency galactosemia, there are also other rare types of
galactose metabolism diseases, Type II Galactosemia
(OMIM 230200), caused by deficiency of the enzyme
Galactokinase (GALK, EC 2.7.1.6), characterized by
early onset bilateral cataract and some neurological mani-
festations [26], and type III Galactosemia (OMIM #230350)
caused by mutations in GALE gene (EC 5.1.3.2) leading to
UDP-galactose 4-epimerase deficiency [27].
The aim of this study is to describe the profile of
mutations in the GALT gene of the Brazilian patients
with CG and for newborns that present positive galacto-
semia newborn screening test, in addition to studying the
genotype-phenotype correlation. This study provides some
information for discussions about the introduction of
Galactosemia in the national newborn screening pro-
gram in Brazil, where the prevalence of CG is estimated
close to 1:20,000 [28].
Methods
Patients and ethical aspects
Thirty patients (60 alleles), including two sib pairs, who
have the diagnosis of Galactosemia confirmed by bio-
chemical analysis, were analyzed. The patients come
from the Clinical Hospital of the Ribeirão Preto Medical
School, University of São Paulo (8 patients) and other
services and hospitals in Brazil (22 patients). Six patients
of the study were diagnosed through expanded newborn
screening test, which is not available as routine for all
newborns in Brazil. Clinical data of patients were ob-
tained from a review of the medical records, using a
standardized form. The Research Ethics Committee of
the Hospital approved the study and a written informed
consent was obtained from each patient or responsible
family member.
Red blood cell GALT assay
The GALT enzyme activity was detected by an enzymatic-
fluorometric method [29]. The fluorescence reading at
460 nm was obtained with a Hitachi F-2000 fluorometer
(Hitachi, Tokyo, Japan) and to measure haemoglobin
concentration, an absorbance reading at 410 nm was
obtained with a Hitachi U-2001 spectrophotometer (Hitachi,
Tokyo, Japan). The normal range was defined as 37–
66 μmol/h per gHb.
DNA amplification and exon sequencing
All patients were subjected to exons sequencing of the
GALT gene. In order to diagnose a possible galactosemia
due to galactokinase deficiency, one patient with elevated
total galactose and normal erythrocyte GALT enzyme ac-
tivity also underwent GALK1 gene exons sequencing.
Genomic DNA was extracted from peripheral blood
leukocytes, using a Super Quick-gene-rapid DNA isolation
kit (Promega, Madison, WI, USA), following the manufac-
turer’s instructions. Eight pairs of primers were designed to
amplify the promoter region, the 11 exons and adjacent in-
tronic regions of the GALT gene. For the analysis of the
GALK1 gene, six pairs of primers were designed to cover
the eight exons and their respective splice site junctions
(primer sequences and PCR conditions in Additional file 1).
The PCR-amplified DNA fragments were subjected to
direct sequencing in an automatic capillary sequencing
system ABI 3130 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA), using the Big Dye® terminator
v3.1 cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA) and the same PCR primers, following the
manufacturer’s instructions. The results were analyzed
using the FinchTV version 1.4.0 (Geospiza, Seattle, WA,
USA) and Codoncode Aligner (Codoncode, Centerville,
MA, USA). The sequences obtained were compared with
the reference ones from GenBank database (NG_009029.1/
NM_000155.3 and NG_008079.1/NM_000154.1).
In silico analysis
In order to predict damage effects of missense and splice
site mutations, we performed in silico simulations using
the following bioinformatics tools: 1) SIFT [30], that
classify variants according to mathematical operations; 2)
PolyPhen2 [31], that uses Bayesian methods, and; 3) BDGP
Splice Site Prediction software, a system that evaluate
changes in splice site strength based on by Neural Net-
work models [32].
Results
The average age of diagnosis was about one and a half
month, excluding from this calculation the patient with
48 years of old. During the review of patients’ records
and analyzing the standardized form data of patients
from other participating centers, it was observed as the
main clinical findings: hepatomegaly, jaundice, hemolytic
anemia, failure to thrive and bilateral cataract. Some pa-
tients show developmental delay and the only adult pa-
tient included has primary ovarian insufficiency (Table 1).
DNA sequencing analysis identified 18 different patho-
genic mutations on the GALT gene (Table 2), the two
with higher relative allelic frequency were the c.563A >
G[p.Q188R] (22 %) and c.404C > T[p.S135L] (12 %). We
also identified the Duarte allele and seven new mutations:
c.2 T > C[p.M1T], c.97C > A[p.R33S], c.217C > T[p.P73S],
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Table 1 Clinical summary of patients with galactosemia and results of GALT enzyme activity assay, and genotyping
Age at
diagnosis
Age at last
evaluation
Hepatomegaly Jaundice Vomiting Failure to
thrieve
Cataracts Hemolytic
anemia
Ataxia/Ovarian failure GALT activity
(μmol/h/g Hb)
GALT Genotype Diagnosis
1 2 m 4y + + + + - + - Undetectable p.Q188R/p.Q188R Classical galactosemia
2 2 m 10 m + + + + - - - 5.0 p.Q188R/p.Q188R Classical galactosemia
3 1 m 12 m + + - - - - - 3.1 p.Q188R/p.Q188R Classical galactosemia
4 4 m 5 m + + - - - - - 1.5 p.Q188R/p.Q188R Classical galactosemia
5 1 m 2 m + + + - + - - 14.5 p.Q188R/p.K285N Classical galactosemia
6 1½m 5y + + - + - - - 11.0 IVS3nt + 1G > A/p.Q188R Classical galactosemia
7 1 m 16 m + + + + - - - Undetectable p.Q169P/p.Q188R Classical galactosemia
8 NS 2y - + - + - - - 13.3 IVS4nt + 4A > C/p.Q188R Classical galactosemia
9 ½m 12 m + + + + - - - Undetectable p.M1T/p.Q188R Classical galactosemia
10 2 m 4y + - + + - - - Undetectable p.S135L/p.Q188R Classical galactosemia
11 1 m 3y + + + - + - - Undetectable p.S135L/p.Q188R Classical galactosemia
12 NS 5 m - + - + - + - Undetectable p.S135L/p.G175D Classical galactosemia
13 4½m 4y + + - - + + - Undetectable p.S135L/p.K285N Classical galactosemia
14 2 m 2 m + + - + - - - Undetectable p.S135L/p.L275fs Classical galactosemia
15 1 m 3 m + - + + - - - Undetectable p.S135L/p.F171S Classical galactosemia
16* 2 m 3 m¢ + + - + + - - 1.5 p.M1T/p.S135L Classical galactosemia
17* 1 m 5y + - - + - + - 1.0 p.M1T/p.S135L Classical galactosemia
18 3 m 2y + + + + - - - 12.0 p.R33H/p.S135L Classical galactosemia
19 1½m 3y + + + + + + - Undetectable IVSnt4 + 4A > C/p.R231H Classical galactosemia
20 NS 10 m - - - - - - - 3.0 p.P73S/p.N314D§ Duarte galactosemia
21 2 m 3 m - + - - - - - 10.0 p.G175D/N314D§ Duarte galactosemia
22# NS 5 m - - - - - - - 13.0 p.R204X/N314D§ Duarte galactosemia
23# NS 17 m - - - - - - - 19.0 p.R204X/N314D§ Duarte galactosemia
24 NS 4 m - - - - - - - 29.0 p.Q188R/N314D§ Duarte galactosemia
25 NS 2 m - - - - - - - 29.8 p.N97del/p.N314D§ Duarte galactosemia
26 3 m 4y + - - - - - - 7.0 p.H132Y/p.T292Tp.H315H Galactosemia allele carrier
27 NS 3 m - - - - - - - 13.0 p.I170I/p.Q188R Galactosemia allele carrier
28 48y 48y - - - - - - + 21.0 p.R33S/p.S293S Galactosemia allele carrier
29 2 m 28 m - - - - - - - 33.0 WT/p.P325L Galactosemia allele carrier
30@ NS 3 m - - - - - - - 47.0 WT/WT Galactosemia type 2
NS = Newborn screening; m =months; y = years; *sip pair, #sib pair, ¢died at 3 month of age
§ = Duarte allele: c.-119_-116delCAGT + c.508-24G > A + c507 + 62G > A + N314D
@GALK1 genotype: c.166-5_c.227dup67 and c.766C > T (p.R256W)
New mutations are indicated in bold
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Table 2 GALT mutations in the Brazilian patients with galactosemia
Region nucleotide change Mutation type Amino Acid Damage Prediction
by SIFT
Damage Prediction
by Polyphen-2
Classification@ Relative allele frequency References
5′UTR -119_-116delCAGT* deletion — — — Benign (Duarte 2) 0,08 Berry GT et al., 2001 [44]
Exon 1 c.2 T > C missense M1T DAMAGING TOLERATED Pathogenic 0,04 novel
Exon 2 c.97C > A missense R33S DAMAGING DAMAGING Pathogenic 0,01 novel
Exon 2 c.98G > A missense R33H DAMAGING DAMAGING Pathogenic 0,01 Gort L et al., 2006 [45]
Exon 2 c.217C > T missense P73S TOLERATED DAMAGING Predicted pathogenicity 0,01 novel
Exon 3 c.287_289delACA deletion N97del — — Pathogenic 0,01 novel
Intron 3 c.328 + 1G > A splicing efect# — — — Predicted pathogenicity 0,01 novel
Intron 4 c.377 + 4A > C splicing efect# — — — Predicted pathogenicity 0,03 novel
Exon 5 c.394C > T missense H132Y DAMAGING DAMAGING Pathogenic 0,01 Elsas LJ et al., 1998 [46]
Exon 5 c.404C > T missense S135L DAMAGING DAMAGING Pathogenic 0,12 Reichardt JK et al., 1992 [47]
Exon 5 c.506A > C missense Q169P DAMAGING DAMAGING Pathogenic 0,01 novel
Intron 5 c.508-24G > A* polymorphism — — — Benign 0,08 Kozak L et al., 2000 [48]
Intron 5 c.507 + 62G > A* polymorphism — — — Benign 0,08 Kozak L et al., 2000 [48]
Exon 6 c.510C > A silent I170I TOLERATED TOLERATED Translationally silent 0,01 Item C et al., 2002 [49]
Exon 6 c.512 T > C missense F171S DAMAGING DAMAGING Pathogenic 0,01 Reichardt JK et al., 1992 [47]
Exon 6 c.524G > A missense G175D DAMAGING DAMAGING Pathogenic 0,03 Gort L et al, 2006 [45]
Exon 6 c.563A > G missense Q188R DAMAGING DAMAGING Pathogenic 0,22 Reichardt JK et al., 1992 [47]
Exon 7 c.610C > T nonsense R204X — — Pathogenic 0,03 Tyfield L et al., 1999 [35]
Exon 8 c.692G > A missense R231H DAMAGING DAMAGING Pathogenic 0,01 Ashino J et al., 1995 [41]
Exon 9 c.824delT deletion L275Qfs*5 — — Pathogenic 0,01 Elsas LJ et al., 1998 [46]
Exon 9 c.855G > T missense K285N DAMAGING DAMAGING Pathogenic 0,03 Leslie ND et al., 1992 [33]
Exon 9 c.876G > A silent T292T TOLERATED TOLERATED Translationally silent 0,03 Calderon FR et al., 2007 [17]
Exon 9 c.879C > T silent S293S TOLERATED TOLERATED Translationally silent 0,01 Calderon FR et al., 2007 [17]
Exon 10 c.940A > G* missense N314D TOLERATED TOLERATED Benign (Duarte 1 and 2) 0,08 Reichardt JK et al., 1991 [50]
Exon 10 c.945 T > C silent H315H TOLERATED TOLERATED Translationally silent 0,03 Lai K et al., 1996 [21]
Exon 10 c.974C > T missense P325L DAMAGING DAMAGING Pathogenic 0,01 Greber-Platzer S et al., 199 [51]7
*these mutations are found in cis in Duarte 2 allele
#
@
New mutations are indicated in bold
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c.287_289delACA[p.N97del], c.328 + 1G > A[IVS3 +
1G > A], c.377 + 4A > C[IVS4 + 4A > C] and c.506A >
C[p.Q169P] (Fig. 1). Six of these new mutations were in
heterozygous with frequent ones (IVS3 + 1G >A/p.Q188R,
IVS4 + 4A >C/p.Q188R, p.M1T/p.S135L, p.M1T/p.Q188R,
p.P73S/p.N314D, p.N97del/p.N314D and p.Q169P/
p.Q188R). Patients who carried new mutations showed
reduced or undetectable GALT enzyme activity (Table 1).
Four patients were genotyped as homozygous for the
allele p.Q188R, one patient was heterozygous for wild
type and p.P325L allele and three were heterozygous for
a CG mutation with predicted translationally silent mu-
tations (p.H132Y/p.T292T + p.H315H, p.R33S/p.S293S
and p.I170I/p.Q188R). The majority of the patients (22)
were genotyping as compound heterozygotes for two of the
following mutations: p.M1T, p.R33H, p.P73S, p.N97del,
IVS3 + 1G >A, IVS4 + 4A >C, p.S135L, p.Q169P, p.F171S,
p.G175D, p.Q188R, p.R204X, p.R231H, p.L275Qfs*5,
p.K285N, p.N314D and p.P325L (Table 1).
Interestingly, a patient who has been identified by
neonatal screening with high total galactose level had
normal GALT activity assay and no mutation in the
coding region of GALT gene. Further analysis revealed
that the patient had type II galactosemia, caused by two
mutations in GALK1 gene: c.166-5_c.227dup67 and
p.R256W (Fig. 2).
Discussion
In order to characterize the molecular basis of the galac-
tosemia in Brazil, we analyzed samples from 30 patients
suspected to have galactosemia. The results revealed 26
different GALT mutations and two on the GALK1 gene,
with an average rate of pathogenic alleles detection of
93 % (56/60). The p.Q188R mutation was the most fre-
quent (22 %), followed by the p.S135L (12 %) and the
Duarte allele (8 %). The mutation p.M1T was found in
two independent alleles (three patients, including a pair
of brothers), and IVS4 + 4A > C, p.G175D and p.R204X
were identified in two alleles each, with p.R204X also
present in brothers. The mutations p.M1T, p.R33S, p.P73S,
p.N97del, IVS3 + 1G >A, IVS4 + 4A >C and p.Q169P iden-
tified in this study have never been previously described.
Regarding the new mutations, we looked for these muta-
tions in different databases from normal individuals (1000
genomes, HapMap, dbSNP) and cancer patients (COS-
MIC). As we did not identify any of them in these da-
tabases, we are confident to firm that all the variants
are considered novel.
Regarding the phenotype, it was observed a broad clin-
ical spectrum, ranging from a rapidly progressive pheno-
type with hepatic failure that results in death in the third
month of life, to more slowly progressive forms, in
which were observed only mild hepatomegaly.
For patients who received the diagnosis after a specific
clinical situation, it was possible to establish a genotype-
phenotype correlation. Patients who were homozygous
for the p.Q188R mutation presented more severe pheno-
type, as well as the patient with undetectable GALT
activity who is compound heterozygous for the mutation
p.Q188R and new one p.Q169P. Both mutations are in a
highly conserved domain [33, 34]. The p.Q188R muta-
tion is more common in European populations or those
predominantly of European origin [35]. Individuals
homozygous for p.Q188R allele tend to have a severe
Fig. 1 Electropherograms of the novel GALT mutations identified in this study
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phenotype and about 10 % of normal enzymatic activity,
as observed in in vitro expression systems [36, 37].
The compound heterozygous patient for mutations
p.Q188R and IVS3 + 1G >A also showed a severe pheno-
type, progressing to cirrhosis before starting treatment.
She had a history of a sister who died of liver failure at
two months of age of unknown cause. We postulate that
the single base change G-to-A that corresponds to a
change in the 5′-GU splice donor site of Intron 3 makes
the site unrecognizable to the splicing enzymes, with a
consequent excision of the exon 3 in the mRNA and pro-
duction of a truncated protein. It is exactly what happens,
for example, with the common mutation of Phenylketon-
uria IVS12 + 1G >A, that causes skipping of the 12th exon
when RNA is being spliced [38]. Some mutations were
described at the splice donor site of other introns in CG
patients [17, 18, 39].
The proband who had the mutations p.M1T and
p.S135L, at the age of two months, showed anemia,
hepatomegaly, bilateral cataracts and ascites, progres-
sing in a month to hepatic failure, dehydration and
hepatic encephalopathy. She was diagnosed with CG,
but her clinical status was so severe that she died due
to septic shock, shortly after starting the diet. Her brother,
who was born one year after, was diagnosed within the first
month of life and began the treatment early. He is currently
5 years old and shows a good clinical outcome, presenting
only with a slight enlarged liver and mild bilateral nuclear
cataract. The p.M1T mutation was also found in heterozy-
gous with p.Q188R in a patient diagnosed soon after birth
with a classic severe phenotype.
The p.M1T should be considered a severe mutation
because affects the start codon and might cause out-of-
frame usage of the next AUG triplet, 112 nucleotides
downstream; it is therefore expected to produce an un-
stable nonfunctional protein. So the fact that it was con-
sidered benign by polyphen-2 although pathogenic by
SIFT may be because the polyphen-2 consider structural
change that the mutation causes to the protein and does
not take into account the fact that the protein is truncated.
Other individuals with a p.S135L mutation had an acute
moderate phenotype, which was consistent with what is de-
scribed in the literature. The p.L135 allele is found almost
exclusively in people of African descent and individuals car-
rying this allele have residual enzyme activity of GALT in
some tissues and a less severe phenotype [21, 40].
The only adult patient included in this study was a
48 years woman, presenting with a primary ovarian failure,
ataxia and a moderate residual GALT enzyme activity. She
had no other symptoms and during the genotyping only
the missense new mutation p.R33S and the mutation/
polymorphism p.S293S were detected.
Two unrelated patients from different geographical
regions of Brazil have the IVS4 + 4A > C mutation. The
in silico splicing analysis revealed that this mutation
abolishes the donor splicing site (donor score <0.40).
Therefore, the IVS4 + 4A > C may be considered as a
pathogenic mutation. One is a compound heterozygote
with the p.Q188R mutation, and the other with the
p.R231H mutation. Both showed a good clinical outcome.
The first was diagnosed through expanded neonatal screen-
ing test and therefore started treatment early. The second
one was with jaundice and hepatomegaly at 15 days of age
and was diagnosed a month later, when in addition, he pre-
sented cataracts. The p.R231H mutation was first described
in a Japanese patient, it is predicted to reduce to 15 % of
normal controls the GALT enzyme activity in a COS cell
expression system [40] and has no detectable activity
Fig. 2 Electropherograms of the GALK1 mutations identified in the patient with galactosemia type II
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when expressed in E. coli BL21 cells [37], as observed
in this patient.
The most common variant of the gene is the Duarte
(D2) allele, that is generally not associated with a clinical
phenotype when in homozygous, and when in heterozy-
gous with a disease-causing mutation can trigger a mild
form of galactosemia called Duarte galactosemia [23]. In
this study, six Duarte alleles have been identified (10 %).
All individuals with Duarte galactosemia, except one,
were diagnosed through expanded newborn screening
test, including the compound heterozygotes D2/p.P73S
and D2/p.N97del.
The p.P73S mutation is considered tolerable in SIFT
and probably damaging by the Poliphen-2. This individual
is asymptomatic, even without diet restriction and despite
the low enzymatic activity, therefore it is not possible to
establish whether this new mutation is pathogenic or not,
additional functional studies are necessary.
The only patient with Duarte galactosemia who was
diagnosed after a clinical suspicion, is compound hetero-
zygote D2/p.G175D and had only prolonged neonatal
jaundice. This patient has an enzyme assay below the
normal range and was in a galactose restriction diet.
The patient heterozygous for the p.P325L was asymptom-
atic but had a positive newborn screening test for galacto-
semia, the first GALT activity was 12 umol/h/gHb and the
second, at two month of age, was 33 umol/h/gHb. As she
had a normal total galactose assay (4,3 mg/dl), the breast-
feeding was kept and she remained without symptoms.
Definitely, with the availability of neonatal screening test
for Galactosemia routinely in some countries, the clinical
outcome improved a lot. The greatest benefit derived from
this approach is that it is possible to introduce therapy be-
fore the onset of acute severe complications. However, it is
noteworthy that not every positive test is followed by the
diagnosis of CG. Many positive tests are due to variant
Duarte and some to other forms of Galactosemia. There-
fore, after a positive test, it is important apart from starting
treatment, make quickly a careful clinical assessment and
perform genotyping, in order to determine whether the
patient will be kept in galactose restriction diet.
Conclusions
Genetic heterogeneity documented to date, undoubtedly
contributes to the phenotypic heterogeneity that is ob-
served in galactosemia. Additional effects of non-allelic
variation and other constitutional factors on phenotypic
variability remain to be elucidated. The present study
characterized the phenotypic and genotypic profile of
some patients with classic galactosemia in the Brazilian
population, which is considered one of the most heteroge-
neous in the world, as a result of more than five centuries
of miscegenation among mainly three ancestral roots: the
indigenous Amerindians, Europeans and sub-Saharan
Africans. The heterogeneity and admixture have import-
ant implications in the current genetic background of the
population [42, 43] that has a high estimated prevalence
of CG compared with other populations [28]. This is the
first genotyping study in Brazilian patients with diagnosis
of Galactosemia.
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